Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1001 of 6351
-
Head and neck cancer trial halted: did xevinapant fall short?
Disease control Stopped earlyThe primary objective of the study was to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New cocktail of drugs and targeted procedure aims to control liver cancer
Disease control Recruiting nowThis is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative…
Phase 2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Radiation boost may keep melanoma at bay for immunotherapy patients
Disease control Recruiting nowThis phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without completion lymph node dissection. Prior studies of patien…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for lymphoma patients who can't handle standard drug
Disease control OngoingThis phase II trial studies how well acalabrutinib works in treating patients with mantle cell lymphoma that cannot tolerate ibrutinib. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo tackles Platinum-Resistant gynecologic cancers
Disease control OngoingThis phase II trial studies the side effects and how well brachytherapy with durvalumab or tremelimumab work for the treatment of gynecological malignancies that is resistant to platinum therapy (platinum-resistant), does not respond to treatment (refractory), has come back (recu…
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Triple-Drug cocktail shows promise against rare neuroendocrine tumors
Disease control OngoingThis phase II trial studies how well the combination of XL184 (cabozantinib), nivolumab, and ipilimumab work in treating patients with poorly differentiated neuroendocrine tumors (i.e., neuroendocrine tumor that does not look like the normal tissue it arose from). Cabozantinib ma…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThe primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial…
Phase 1/2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo therapy aims to outsmart resistant head and neck cancer
Disease control CompletedResearchers are looking for new ways to treat people with head and neck cancer whose cancer has come back after treatment (recurrent) or whose cancer has spread to other parts of the body (metastatic). Some people with recurrent or metastatic head and neck cancer are treated with…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Less invasive surgery may improve recovery for ovarian cancer patients
Disease control Recruiting nowThis phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemotherapy). MIS is a surgical procedu…
Phase 3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Hope for duchenne: new cell therapy shows promise in Long-Term trial
Disease control OngoingThis Phase 2, multi-center, open-label extension trial will provide deramiocel (CAP-1002) to subjects that were enrolled in the HOPE-2 trial and completed 12 months of follow-up. The trial will explore the safety and efficacy of twenty intravenous administrations of deramiocel, e…
Phase 2 • Sponsor: Capricor Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Patients choose: transplant or Non-Transplant for rare bone marrow cancer?
Disease control OngoingThe purpose of this research study is to see how effective hematopoietic stem cell transplantation (HCT) is compared to best available non-transplant therapies (BAT) in patients with high risk myelofibrosis. This will be done by asking participants to choose the treatment that th…
Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can a short, High-Dose radiation blast before surgery improve breast cancer care?
Disease control Recruiting nowThe purpose of this study is to find the most effective dose of radiation therapy to give to breast tumors in a shorter period of time, prior to standard partial mastectomy/axillary surgery.
Sponsor: University of Miami • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a brief blood thinner pause prevent bleeding without raising stroke risk?
Disease control CompletedThis study aims to analyze the safety and effectiveness of the discontinuation/resumption protocol of factor Xa inhibitors before and after invasive procedures/surgeries in non-valvular atrial fibrillation patients who are at risk of minor bleeding in actual clinical settings
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Radioactive Bone-Seeking drug paired with chemo shows promise for advanced breast cancer
Disease control OngoingThis phase II trial studies how well radium-223 dichloride and paclitaxel work in treating patients with advanced breast cancer that has spread to the bones. Radium-223 dichloride is a radioactive drug that behaves in a similar way to calcium and collects in cancer that has sprea…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New rabies vaccine shows promise in large thai trial
Vaccine CompletedPrimary Objective: To describe the immune response induced by VRVg-2 and Verorab vaccine at Day 14 (to assess the immune response after 3 doses \[2-2-2\]) and Day 42 (to assess the immune response after 4 doses \[2-2-2-0-2\]) when administered as standalone in healthy pediatric …
Phase 3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Vaccine
Last updated Jun 26, 2026 18:58 UTC
-
AI and home videos could spot cerebral palsy months earlier
Diagnosis OngoingCerebral Palsy (CP) is the most common motor dysfunction in childhood. Traditionally, diagnosis is set between 12 and 24 months of age. This study will evaluate feasibility of a new screening procedure for early detection of CP in high-risk infants and investigate how such a proc…
Sponsor: St. Olavs Hospital • Aim: Diagnosis
Last updated Jul 23, 2026 00:00 UTC
-
Can a Patient's own immune cells be trained to fight pancreatic cancer?
Disease control Recruiting nowThis is a phase 1, first in human, dose escalation study for safety and feasibility of multi-dose dendritic cell (DC) therapy for pancreatic ductal adenocarcinoma (PDAC) including adenosquamous carcinoma administered after surgical resection of PDAC.
Phase 1 • Sponsor: Diakonos Oncology Corporation • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Heart-Lung machine save kids with septic shock?
Disease control Recruiting nowSevere sepsis and septic shock remain the leading causes of child mortality worldwide. Sepsis is a complex process that ultimately leads to circulation disorders, organ perfusion abnormalities, capillary leakage, tissue hypoxia, and organ failure. The difficulty of clinical treat…
Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy shows promise for tough lymphoma cases
Disease control CompletedThis is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19/22 CART cells combined with PD-1 Inhibitor in relapsed/refractory B Cell Lymphoma.
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Can a vaccine cocktail free HIV patients from daily pills?
Disease control CompletedCombination approaches will almost certainly be required to generate durable control of HIV in the absence of antiretroviral therapy (a "remission"). In this study, 20 individuals will receive a combination regimen administered during ART and then undergo an analytic treatment in…
Phase 1/2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC